Axonics® announces proposed public offering of common stock

Irvine, calif.--(business wire)--axonics, inc. (nasdaq: axnx) (“axonics”), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that it has commenced a proposed underwritten public offering of 1,750,000 shares of its common stock. axonics expects to grant the underwriter a 30-day option to purchase up to an additional 262,500 shares of its common stock. axonics anticipates using the net proc
AXNX Ratings Summary
AXNX Quant Ranking